R

Rajnandani

Active Director Director DIN 10200091
DIN 10200091 First appointment Apr 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2023
Shareholding value •••• Premium profile

About Rajnandani

Data last updated:

Rajnandani is a Director at Unirust Pharma Private Limited (since 2023). Unirust Pharma Private Limited reported revenue of ₹12 Lakh (FY 2025).

DIN 10200091
Primary Designation Director
First Appointment 19 Apr 2023
Oldest Company Age 3 yrs
Largest company Unirust Pharma Private Limited · ₹12 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Unirust Pharma Private Limited U46497PN2023PTC219688
Director19 Apr 20232023₹12 Lakh (FY 2025)Active

Board colleagues of Rajnandani

NameDINCompanyDesignation
Mala Sharma10122542Unirust Pharma Private LimitedDirector
Pankaj Kumar10122543Unirust Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Unirust Pharma Private Limited
Premium access

Shareholding and investment profile for Rajnandani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajnandani

Rajnandani currently holds 1 directorship: Unirust Pharma Private Limited (Director, since 19 Apr 2023, revenue ₹12 Lakh (FY 2025)).

Rajnandani was first appointed on 19 Apr 2023 as Director at Unirust Pharma Private Limited.

The current boards of Rajnandani's companies include Mala Sharma (Unirust Pharma Private Limited), Pankaj Kumar (Unirust Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available